Alexander Bystritsky

Alexander Bystritsky practices at Resnick Neuropsychiatric Hospital at UCLA in Los Angeles, California.

Alexander Bystritsky's NPI, 1053428011, was assigned on August 24, 2006. Alexander Bystritsky holds California license A41302.

Alexander Bystritsky's primary practice is Resnick Neuropsychiatric Hospital at UCLA, at 150 Ucla Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 267-9308.

Alexander Bystritsky's primary practice is Resnick Neuropsychiatric Hospital at UCLA in Los Angeles, California. The medical group on file is UCLA Health. Dmand AI also links Alexander Bystritsky to 1 more physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Alexander Bystritsky practices, 2 sites in all. Vendor and product names are available with a free account.

Psychiatry is Alexander Bystritsky's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Alexander Bystritsky is licensed in California.

CMS data shows 55 Medicare services from Alexander Bystritsky across 2 procedure codes in 2017, all of them office visits. Medicare paid $3,998 for them. Every service was in an office.

Across all payers, Dmand AI patient panel data puts Alexander Bystritsky's median patient age at 41, with 50% women.

In 2024, Alexander Bystritsky wrote 171 Medicare Part D claims for 14 patients. 96% of them were for generic drugs. CMS names the drug for 102 of them, across 6 drugs with 11 or more claims each, at $728 in total drug cost. In 2023, CMS named 110 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Alexander Bystritsky for performance year 2024, reported as part of a group. Alexander Bystritsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Alexander Bystritsky to 6 clinical trials. Conditions studied include Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders and Fibromyalgia. ACADIA Pharmaceuticals Inc. sponsors the most, 2. Open Payments lists research payments to Alexander Bystritsky that name 6 trials.

CMS Open Payments shows 69 general payments to Alexander Bystritsky from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 68% of the total. Otsuka Pharmaceutical Development & Commercialization, Inc. paid the most, $7,643. It also lists 64 research payments totaling $87,351 from 2016 to 2022, naming 6 clinical trials.